| Type 2 Diabetes Mellitus |
1 |
1 |
| Social Determinants of Health |
0 |
1 |
| GLP-1 Receptor Agonist |
0 |
0.9 |
| Revenue and Practice Management |
0 |
0.51 |
| Drug Costs |
0 |
1 |
| Match |
0 |
0.37 |
| Receptors |
0 |
0.37 |
| SGLT2 Inhibitor |
0 |
0.9 |
| Medical Life |
0 |
0.36 |
| Cardiovascular Risk Management |
0 |
0.32 |
| Cardiovascular disease |
0 |
0.28 |
| Hypertension |
0 |
0.28 |
| Insurance |
0 |
0.28 |
| Coronary Artery Disease (CAD) |
0 |
0.26 |
| Salary and Compensation |
0 |
0.18 |
| Lipids Management |
0 |
0.15 |
| Hemoglobin A1c |
0 |
0.13 |
| Antihypertensive Agents |
0 |
0.09 |
| Child |
0 |
0.09 |
| Dorsum |
0 |
0.09 |
| Endocrinology |
0 |
0.09 |
| Generics |
0 |
0.09 |
| Health Plans |
0 |
0.09 |
| Health Policy |
0 |
0.09 |
| Hemoglobin |
0 |
0.09 |
| Medicare |
0 |
0.09 |
| Prescription Drugs |
0 |
0.8 |
| Statins |
0 |
0.09 |